Traduction de «will file an amicus » (Néerlandais → Français) :

The US Department of Labor has indicated that it will file an amicus brief on behalf of plaintiffs.
Le Département du travail américain a indiqué qu’il déposerait une requête («amicus brief») en faveur des plaignants.

Amicus briefs supporting the plaintiffs’ position were filed by the National Employment Lawyers Association and by the US Department of Labor, and the US Chamber of Commerce filed a brief in support of NPC. On July 6, 2010, the Second Circuit vacated the judgment of the SDNY and remanded the case to the SDNY for further proceedings.
Les demandeurs ont fait appel de ce jugement devant la Cour d’appel de deuxième instance. L’association nationale des avocats de l’emploi (National Employment Lawyers Association), le Département américain du travail ont déposé des «amicus briefs» (requêtes) en faveur des demandeurs, tandis que la Chambre de commerce américaine a fait de même en faveur de NPC. Le 6 juillet 2010, la deuxième instance a invalidé le jugement du SDNY et lui a renvoyé le cas en lui demandant de statuer à nouveau.

The US Department of Labor filed an amicus brief on behalf of plaintiffs.
Le Département du travail américain a déposé une requête («amicus brief») pour le compte des plaignants.

Amicus briefs supporting the plaintiffs’ position were filed by the National Employment Lawyers Association and by the US Department of Labor.
L’association nationale des avocats de l'emploi (National Employment Lawyers Association) et le Département américain du travail ont déposé des «amicus briefs» (requêtes) en faveur des demandeurs.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Additionally, a model will also be developed for a uniform working method for handling files, exchanging information and other tasks within the unit.
Additionally, a model will also be developed for a uniform working method for handling files, exchanging information and other tasks within the unit.